Blood test ratios and diabetes complications
Part of Hormones & metabolism clinical trials.
This study looks at two simple blood test ratios (uric acid/HDL and monocyte/HDL) to see if they can help predict diabetes-related complications. It may give doctors a new way to catch problems early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have type 2 diabetes.
- You must be 18 years old or older.
- You cannot be pregnant.
- You cannot have cancer, an autoimmune disease, chronic kidney disease, or gout.
- You cannot take certain medicines like furosemide, thiazide, aspirin, losartan, or cholesterol-lowering drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures how certain blood “fat” markers relate to blood sugar control and inflammation. It may help researchers understand risk factors for heart disease in people with type 1 or type 2 diabetes, pre-diabetes, and people preparing for weight-loss surgery.
This study looks at how certain blood cell ratios relate to blood sugar control and blood vessel problems in people with type 2 diabetes. It helps doctors understand which patients might be at higher risk for complications.
This study looks at whether the ratio of two types of cholesterol (non-HDL to HDL) is linked to kidney damage in people with diabetes. It aims to help identify those at higher risk for diabetic kidney disease.
This study looks at people with diabetes to understand how diabetes complications are linked to heart and stroke risk. It may help doctors better predict risk and guide prevention in the future.
This study measures immune cells from your blood to find markers (biomarkers) that may explain or predict diabetic cardiomyopathy, a type of heart condition linked to diabetes. You may benefit mainly by being closely monitored and contributing to research that could improve future diagnosis or risk tracking.
This study measures “circulating biomarkers” (blood-based signals) in people with type 1 or type 2 diabetes, and in some people without diabetes who test positive for certain diabetes antibodies. The goal is to understand what these blood signals can tell us about diabetes development and progression.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.